10-Q: CV Sciences Reports Q3 2024 Results, Navigates Competitive Market and Financial Challenges

CV Sciences reports a net loss for Q3 2024, with a slight decrease in revenue and ongoing efforts to manage costs and explore strategic opportunities.

Summary

• CV Sciences reported a net loss of $456,000 for the third quarter of 2024, consistent with the loss in the same period of 2023.
• Net product sales for Q3 2024 were $3.865 million, a decrease from $4.089 million in Q3 2023.
• Gross profit for Q3 2024 was $1.778 million, slightly down from $1.843 million in Q3 2023, but gross margin improved to 46.0% from 45.1%.
• For the nine months ended September 30, 2024, the company's net loss was $1.668 million, compared to a net income of $3.971 million in the same period of 2023, primarily due to a one-time benefit in 2023.
• The company's net product sales for the first nine months of 2024 were $11.821 million, a decrease from $12.203 million in the same period of 2023.
• Gross profit for the first nine months of 2024 was $5.491 million, up from $5.343 million in the same period of 2023, with gross margin improving to 46.5% from 43.8%.
• The company is facing challenges due to a fragmented and competitive market, and is dependent on additional investment capital to fund operations.
• CV Sciences acquired Cultured Foods in December 2023 and Elevated Softgels in May 2024 to expand its product offerings.
• The company engaged Maxim Group LLC as a financial advisor to explore strategic opportunities.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with some positive developments like improved gross margins and strategic acquisitions, but the negative financial results, going concern warning, and ongoing legal issues create a concerning outlook.

Positives

• Gross margin improved in both Q3 and the first nine months of 2024, indicating better cost management and product mix.
• The company successfully acquired Cultured Foods and Elevated Softgels, expanding its product portfolio and market reach.
• CV Sciences secured additional financing through a secured promissory note, providing necessary capital.
• The company is actively managing costs through strategic reductions in headcount and vendor spending.
• The company is exploring strategic opportunities with the help of Maxim Group LLC.

Negatives

• Net product sales decreased in both Q3 and the first nine months of 2024 compared to the same periods in 2023.
• The company reported a net loss for Q3 2024 and for the first nine months of 2024.
• The company is facing intense competition and a lack of a clear regulatory framework.
• The company is dependent on additional investment capital to fund operations and growth initiatives.
• The company's financial operating results and accumulated deficit raise substantial doubt about its ability to continue as a going concern.

Risks

• The company faces intense competition from both licensed and illicit market operators.
• The lack of a clear regulatory framework and differing state regulations create uncertainty and potential barriers to sales.
• The company is dependent on additional investment capital, and there is no assurance that it will be available on favorable terms.
• The company's financial operating results and accumulated deficit raise substantial doubt about its ability to continue as a going concern.
• The company is involved in ongoing legal proceedings, which could have a material impact on its financial condition.
• A recent emergency order in California banning certain hemp products could negatively impact sales.

Future Outlook

The company anticipates being dependent on additional investment capital to fund operations and growth initiatives, and intends to raise funds through capital markets, debt, or lines of credit. The company will continue to work towards increasing revenue and operating cash flows to meet its future liquidity requirements.

Management Comments

• Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operations, growth initiatives and to continue to make and implement strategic cost reductions.
• The Company intends to position itself so that it will be able to raise additional funds through the capital markets, issuance of debt, and/or securing lines of credit.
• Management believes that Mona Jr.'s claims lack merit and intends to vigorously defend the allegations.

Industry Context

The company operates in a highly competitive and fragmented market with a lack of a clear regulatory framework, which is impacting its ability to grow and maintain profitability. The company is also facing challenges due to differing state regulations and uncertainty about the emerging regulation of cannabinoids.

Comparison to Industry Standards

• The company's gross margin of 46.5% for the first nine months of 2024 is within the range of other companies in the consumer packaged goods sector, but the company's net loss is a concern.
• The company's reliance on external funding is a common challenge for smaller companies in the CBD industry, but the company's going concern warning is a significant risk.
• The company's acquisitions of Cultured Foods and Elevated Softgels are similar to strategies employed by other companies in the industry to diversify product offerings and expand market reach.
• The company's engagement of Maxim Group LLC is a common practice for companies seeking strategic alternatives, but the outcome is uncertain.

Legal Proceedings

• The company is involved in a legal dispute with its founder, Michael Mona Jr., regarding taxes on income received by him upon the vesting and settlement of RSU's in 2019.
• The company is also involved in a shareholder derivative suit and a putative class action complaint, both of which are ongoing.

Related Party Transactions

• The company issued shares of common stock to a vendor as compensation for services.
• The company had a settlement agreement with its former President and Chief Executive Officer, Michael Mona Jr., which included stock options and RSU's.

Stakeholder Impact

• Shareholders are impacted by the company's net losses and the going concern warning.
• Employees are impacted by the company's strategic cost reductions, including reductions in headcount.
• Customers may be impacted by the company's ability to continue operations and provide products.
• Suppliers and creditors are impacted by the company's financial challenges and dependence on additional investment capital.

Next Steps

• The company will continue to implement strategic cost reductions.
• The company will continue to evaluate inbound and outbound merger, sale, acquisition or other opportunities.
• The company will work towards increasing revenue and operating cash flows to meet its future liquidity requirements.
• The company will continue to pursue actions to raise additional funds through the capital markets, issuance of debt, and/or securing lines of credit.

Key Dates

Keywords

CBD, hemp, cannabidiol, supplements, financial results, acquisitions, Cultured Foods, Elevated Softgels, regulatory, OTC, Streeterville Capital, Maxim Group